

**Table 4. Crude and Adjusted Rate Ratios of Acute Myocardial Infarction for Current Use of Anti-Inflammatory Agents according to Concomitant Use of Aspirin and Dose of Cyclooxygenase-2 Selective Inhibitors\***

Variable	No Concomitant Use of Aspirin			Concomitant Use of Aspirin			P Value†
	Case-Patients, <i>n</i>	Controls, <i>n</i>	Adjusted RR‡ (95% CI)	Case-Patients, <i>n</i>	Controls, <i>n</i>	Adjusted RR‡ (95% CI)	
No use	440	12 013	1.00 (reference)	353	4667	1.00 (reference)	Reference
NSAIDs	32	724	1.04 (0.71–1.54)	19	238	0.94 (0.57–1.54)	0.73
Naproxen	18	249	1.59 (0.95–2.65)	5	87	0.60 (0.24–1.50)	0.07
Celecoxib	176	4043	1.07 (0.89–1.30)	111	1555	0.88 (0.70–1.10)	0.12
Low-dose§	126	3021	1.04 (0.84–1.28)	82	1155	0.91 (0.70–1.17)	0.38
High-dose	50	1022	1.16 (0.85–1.57)	29	400	0.80 (0.54–1.20)	0.14
Rofecoxib	143	2586	1.37 (1.12–1.68)	96	1122	1.07 (0.84–1.36)	0.09
Low-dose§	135	2432	1.38 (1.12–1.69)	83	1053	1.00 (0.77–1.28)	0.03
High-dose	8	154	1.23 (0.59–2.54)	13	69	2.36 (1.27–4.39)	0.18
Meloxicam	2	92	0.59 (0.14–2.41)	5	40	1.59 (0.61–4.14)	0.25

\* NSAID = nonsteroidal anti-inflammatory drug; RR = rate ratio.

† *P* value for 2-sided test of interaction comparing use and nonuse of aspirin at a significance level of  $\alpha = 0.05$ .

‡ Adjusted for age at index (continuous variable); sex, hypertension, coronary artery disease, cerebrovascular disease, peripheral vascular disease, congestive heart failure, diabetes, respiratory illness, gastrointestinal ulcer disease, thyroid disorders, depression/psychiatric illness, and cancer in the year preceding cohort entry; use of concomitant therapy, including antilipemic agents, anticoagulants, and low-dose aspirin in the year preceding cohort entry; health care utilization, including hospitalizations, outpatient visits to any physician, and outpatient cardiologist visits, in the year preceding the index date; number of different drugs taken, chronic disease score, and Charlson index score in the year preceding the index date; and past use of NSAIDs. Rate ratios are for current users compared with nonusers.

§  $\leq 200$  mg/d and  $\leq 25$  mg/d for celecoxib and rofecoxib, respectively.

||  $> 200$  mg/d and  $> 25$  mg/d for celecoxib and rofecoxib, respectively.